Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead

Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP

What will be the key issues shaping bio/pharma supply chains in 2025? Looking at the impact of potential changes in US tariff and trade policy. Plus, what lies ahead in product-specific supply chains for sterile injectables and antibody drug conjugates. And the latest on how companies are advancing upstream supplier risk monitoring and predictive risk planning, including through digitalization and AI.

Featuring: Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP

Each episode is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights. Or get each episode through:

For a full list of the 2025 podcast episode schedule, click here.

You May Also Like

Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025? 

By
Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important…

Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty? 

By
As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)?  A look at the demand side—size, growth rates, and…

Biomanufacturing: How are Industry Capacity & Supply Chains Trending?

By
What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies, and is there too much capacity or is the market tight? Is biomanufacturing outsourcing…

Parenteral Drug Manufacturing—CDMO Outlook: A Capacity Crunch or Easing?

By
What is the supply and demand outlook for fill–finish capacity in the CDMO/CMO sector? Is a capacity crunch or capacity ease in the making? And how will hot-product areas, such…